Sorrento Therapeutics (NASDAQ: [[ticker:SRNE]]) has fired its chief financial officer, Jiong Shao, according to a regulatory filing.
The San Diego-based company, which is among the biotechs developing potential COVID-19 treatments and tests, didn’t explain why. Sorrento appointed Najjam Asghar, its chief accounting officer, to handle CFO responsibilities as well until the firm finds a successor. Before joining Sorrento in June 2019, Asghar held various roles at medical device company NuVasive (NASDAQ: [[ticker:NUVA]]). Prior he worked at accounting firm PricewaterhouseCoopers.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
